Foghorn Therapeutics (FHTX) EPS (Basic) Growth (1y) (2020 - 2026)
Powered by 
Analysis
Foghorn Therapeutics (FHTX) EPS (Basic) Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 87.85% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 143.95% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 322.67% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -16.29% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.41% |
| 10 | Foghorn Therapeutics | 347.75 Mn | 279.67 Mn | - | 65.85% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 65.85% |
| Mar 31, 2026 | 11.37% |
| Dec 31, 2025 | 0.93% |
| Sep 30, 2025 | 14.46% |
| Jun 30, 2025 | 33.04% |
| Mar 31, 2025 | 45.43% |
| Dec 31, 2024 | 38.14% |
| Sep 30, 2024 | 10.51% |
| Jun 30, 2024 | 36.81% |
| Mar 31, 2024 | 19.14% |
| Dec 31, 2023 | 17.31% |
| Sep 30, 2023 | 44.80% |
| Jun 30, 2023 | -7.16% |
| Mar 31, 2023 | -12.08% |
| Dec 31, 2022 | 9.44% |
| Sep 30, 2022 | 14.57% |
| Jun 30, 2022 | -2.05% |
| Mar 31, 2022 | -1.42% |
| Dec 31, 2021 | 59.85% |
| Sep 30, 2021 | 77.21% |